August 26, 2016 / 15:53 IST
Religare's research report on Aurobindo Pharma
ARBP sustained its growth momentum for yet another quarter, posting strong and in-line EBITDA growth of 23% YoY. The US business saw sequential growth of US$ 10mn, which should continue trending up with impending launches ahead (19 products approved, but not launched). The company is on track to deliver a 21% EPS CAGR over FY16-FY18E led by the US business and a turnaround in the EU business. We remain positive on ARBP and maintain BUY with a Mar’17 TP of Rs 1,000.
For all recommendations, click hereDisclaimer: The views and investment tips expressed by investment experts/broking houses/rating agencies on moneycontrol.com are their own, and not that of the website or its management. Moneycontrol.com advises users to check with certified experts before taking any investment decisions.
Read More
Discover the latest Business News, Sensex, and Nifty updates. Obtain Personal Finance insights, tax queries, and expert opinions on Moneycontrol or download the Moneycontrol App to stay updated!